News

BAWAG Group Reports Strong Q3 2024 Earnings Growth

BAWAG Group Reports Strong Q3 2024 Earnings Growth

BAWAG Group's Performance Highlights for Q3 2024

BAWAG Group has recently unveiled its financial results for the third quarter of 2024, revealing impressive figures that underscore its robust operational performance. The company reported a net profit of € 178 million, which translates to earnings per share (EPS) of € 2.25 and a remarkable return on tangible common equity (RoTCE) of 24.0%. These numbers reflect BAWAG's ongoing commitment to delivering value to its shareholders.

Key Financial Metrics and Year-to-Date Achievements

For the nine months ended in 2024, BAWAG Group reported cumulative results that are equally impressive. The year-to-date net profit reached € 520 million, which is a 3% increase compared to the previous year. This success is complemented by a RoTCE of 23.9% and an EPS of € 6.58, demonstrating consistent growth and stability.

Operational Efficiency and Profit Generation

The pre-provision profit for the third quarter stood at € 265 million, only a slight decline of 1% from the prior quarter. Additionally, BAWAG's cost-income ratio (CIR) was recorded at 32.3%, marking a strategic balance between operational costs and income generation. This ratio reflects effective cost management strategies despite inflationary pressures in the broader economy.

Maintaining Strong Risk Management Practices

In terms of risk management, the risk-cost ratio was held at a solid 0.25%, with the non-performing loan (NPL) ratio remaining stable at 1.0%. These figures indicate BAWAG Group's disciplined approach to risk management, ensuring that they maintain a healthy balance sheet while mitigating potential financial risks.

CET1 Ratio and Regulatory Developments

As of the end of September 2024, BAWAG's Common Equity Tier 1 (CET1) ratio was reported at 17.2%. This figure considers a dividend accrual of € 286 million for the first three quarters of the year. The updated CET1 target is now set at 12.5%, adjusted upward by 25 basis points to support ongoing growth and expansion in a competitive banking environment.

Future Targets and Business Strategy

Looking forward, BAWAG has updated its strategic targets for 2024. The goal is to achieve a profit before tax exceeding € 950 million, with pro forma CET1 above 14.0%, RoTCE greater than 20%, and a CIR of less than 34%. These ambitious targets reflect BAWAG’s proactive approach to business growth and financial stability.

Insights from the CEO

CEO Anas Abuzaakouk emphasized the company's strong third-quarter results, highlighting the strategic initiatives and integration plans in place to enhance overall performance. The recent acquisition of Knab in the Netherlands has received the formal approval from the European Central Bank (ECB), a significant step that opens up new avenues for growth.

Investor Engagement and Upcoming Events

Looking ahead, BAWAG Group plans to engage with investors and stakeholders during an Investor Day scheduled for March 4, 2025. This event will provide further insights into BAWAG's acquisitions, integration plans, and long-term business strategies.

About BAWAG Group

BAWAG Group AG is a prominent financial institution based in Austria, serving approximately 2.1 million customers in various sectors including retail, small businesses, and corporate clients across several European countries and the United States. The group's diverse portfolio includes savings accounts, payment solutions, lending, leasing, and investment services, all designed to meet the evolving needs of its clientele.

Frequently Asked Questions

What are the key financial results for BAWAG Group in Q3 2024?

BAWAG Group reported a net profit of € 178 million and an EPS of € 2.25, with a RoTCE of 24.0%.

How has BAWAG Group's year-to-date performance been?

The year-to-date net profit reached € 520 million, a 3% increase compared to the previous year, with an EPS of € 6.58.

What are the future targets for BAWAG Group?

BAWAG aims to achieve a profit before tax exceeding € 950 million, with a CET1 ratio above 14.0% and RoTCE greater than 20%.

What is the CET1 ratio of BAWAG Group?

As of September 2024, the CET1 ratio was 17.2%, with a target increase to 12.5%.

What is BAWAG Group's strategy moving forward?

BAWAG Group plans to focus on strategic acquisitions, operational efficiency, and maintaining strong capital ratios to support growth and stability in the banking sector.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 3

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 3

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading

Top 5 Most Recently Viewed Articles

Kenmare Resources Welcomes New Dredges to Moma Mine

Updated Category News Views 258

Exciting Developments at the Moma Mine Kenmare Resources plc is a major player in the global mining sector, particularly known for its production of titanium minerals and zircon. Recently, Kenmare achieved a significant milestone with the arrival of its second high-capacity dredge at the Moma Titanium Minerals Mine in northern Mozambique. This advancement represents a...

Continue Reading
Biodesix Reports Strong Q3 2024 Performance and Growth

Updated Category News Views 145

Strong Quarterly Results for Biodesix Biodesix, Inc. (NASDAQ: BDSX), a leader in diagnostic solutions, recently announced impressive financial results for its third quarter, showing remarkable growth compared to the previous year. The company achieved a revenue of $18.2 million, representing a significant 35% increase over Q3 2023. Furthermore, Biodesix's gross profit...

Continue Reading
Innovative Changes at Health In Tech to Boost AI and Revenue

Updated Category News Views 127

Health In Tech Announces Key Leadership Changes Health In Tech (NASDAQ: HIT), a prominent Insurtech platform company known for its innovative third-party AI technology, has implemented significant leadership changes aimed at reinforcing its AI capabilities and propelling company growth. This strategic move is expected to position the company more competitively in the...

Continue Reading
Urgent Notice for KinderCare Learning Investors: Act Now!

Updated Category News Views 169

Important Alert for KinderCare Learning Investors KinderCare Learning Companies, Inc. (NYSE: KLC) is under scrutiny following a significant decline in its stock prices attributed to serious allegations about the company’s operations. The Allegations: What We Know The company conducted its IPO in 2024, offering more than 27 million shares at $24 per share. However,...

Continue Reading
Replimune Group Faces Class Action Lawsuit - Key Details

Updated Category News Views 148

Replimune Group, Inc. Faces Legal Action Replimune Group, Inc. has recently come under the scrutiny of a class action securities lawsuit. This legal action is initiated by Levi & Korsinsky, a law firm known for its role in securities litigation. The lawsuit targets investors who may have experienced losses due to alleged misleading information regarding the company's...

Continue Reading